

**CONFIDENTIAL**Journal - Office of Legislative Counsel
Tuesday - 6 January 1976

Page 2

25X1

5. LEGISLATION Called George Gilbert, OMB, and inquired whether OMB needed a separate letter addressed to them on the bills on congressional oversight before the Senate Government Operations Committee. We have been asked for comments by both the Committee and OMB. Gilbert said a letter to the Committee routed as usual through OMB would be sufficient.

25X1


6. LIAISON Jane McMullan, on the staff of the Senate Appropriations Committee, called to request that someone from the Agency come down and change the combinations on the Committee's safes. I spoke with Office of Security, and made arrangements for two technicians to make the changes tomorrow afternoon. I then advised Jane about our plans.

25X1

7. HEARING Met with Jim Michie, Senate Judiciary Subcommittee on Administrative Practice and Procedure staff, concerning Senator Edward Kennedy's (D., Mass.) informal request that the Agency reconsider the grounds for exempting certain portions of the 1963 IG report on drugs which was released under the Freedom of Information Act. I informed Michie that except for the last sentence of paragraph 9 on page 10, all of the claimed exemptions in the document were reconfirmed. I left with Michie a revised page 10 which included the sentence previously excluded. Michie asked that I meet with him at the earliest opportunity to go over all of the Subcommittee's exhibits of Agency documents in their report to be certain there are no problems.

25X1

25X1

**CONFIDENTIAL**

MORI/CDF Page 1

25X1

relationship. The testing programs are conducted under accepted scientific procedures including the use of control populations, the employment of placebos, and the detailed observation, measurement, recording, analysis, and publication of findings. Where health permits, test subjects are voluntary participants in the program.

9. A current development in the testing of new products is the tightening of controls over dosages and procedures by the U. S. Food and Drug Administration. Since MKULTRA files contained no documentation on this subject, it was not possible to appraise the significance of this development for MKULTRA objectives. However, interviews with the TSD officers concerned indicated that the new rules are affecting procedures and causing controversy in research hospitals and pharmaceutical houses. The TSD officers have close relationships with key individuals in many of the leading U. S. pharmaceutical houses and count on their continued close cooperation in obtaining materials and services deemed vital to U. S. intelligence.

10. The final phase of testing of MKULTRA materials involves their application to unwitting subjects in normal life settings. It was noted earlier that the capabilities of MKULTRA substances to produce disabling or discrediting effects or to increase the effectiveness of interrogation of hostile subjects cannot be established solely through testing on volunteer populations. Reaction and attribution patterns are